摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(S)-tert-butyl 7-oxohexahydropyrrolo[1,2-a]pyrazine-2(1H)-carboxylate | 1190946-32-7

中文名称
——
中文别名
——
英文名称
(S)-tert-butyl 7-oxohexahydropyrrolo[1,2-a]pyrazine-2(1H)-carboxylate
英文别名
tert-Butyl (8aS)-7-oxo-octahydropyrrolo[1,2-a]piperazine-2-carboxylate;tert-butyl (8aS)-7-oxo-1,3,4,6,8,8a-hexahydropyrrolo[1,2-a]pyrazine-2-carboxylate
(S)-tert-butyl 7-oxohexahydropyrrolo[1,2-a]pyrazine-2(1H)-carboxylate化学式
CAS
1190946-32-7
化学式
C12H20N2O3
mdl
——
分子量
240.302
InChiKey
OGPPYSGAQKXGQH-VIFPVBQESA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.5
  • 重原子数:
    17
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.83
  • 拓扑面积:
    49.8
  • 氢给体数:
    0
  • 氢受体数:
    4

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Synthesis and antibacterial activity of 7-(1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazin-7-yl) quinolones
    作者:Bin Zhu、Brett A. Marinelli、Raul Goldschmidt、Barbara D. Foleno、Jamese J. Hilliard、Karen Bush、Mark J. Macielag
    DOI:10.1016/j.bmcl.2009.07.087
    日期:2009.9
    A novel series of 7-(1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazin-7-yl) quinolones has been designed and synthesized in which the heterocyclic side chain is attached to the quinolone core through a carbon–carbon linkage. The antibacterial activity of the compounds was determined against a panel of Gram-positive and Gram-negative pathogens. Compounds 1b and 1e, bearing an 8-methoxy group as well as unsubstituted
    设计并合成了一系列新颖的7-(1,2,3,4-四氢吡咯并[1,2- a ]吡嗪-7-基)喹诺酮,其中杂环侧链通过碳原子连接到喹诺酮核上–碳链。确定化合物对一组革兰氏阳性和革兰氏阴性病原体的抗菌活性。显示了分别带有8-甲氧基以及未取代的和(3S)-甲基取代的1,2,3,4-四氢吡咯并[1,2 - a ]吡嗪-7-基侧链的化合物1b和1e对耐环丙沙星的肺炎链球菌临床分离株具有显着活性。
  • Inhibitors of the renal outer medullary potassim channel
    申请人:MERCK SHARP & DOHME CORP.
    公开号:US10000484B2
    公开(公告)日:2018-06-19
    The present invention provides compounds of Formula (I) (Formula (I)) including pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.
    本发明提供了式(I)化合物(式(I)),包括其药学上可接受的盐,它们是ROMK(Kir1.1)通道的抑制剂。这些化合物可用作利尿剂和/或利钠剂,用于治疗和预防包括高血压、心力衰竭和慢性肾病等心血管疾病以及与盐分和水分过度潴留相关的疾病在内的各种病症。
  • INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL
    申请人:Merck Sharp & Dohme Corp.
    公开号:EP3083573A2
    公开(公告)日:2016-10-26
  • INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIM CHANNEL
    申请人:CHOBANIAN Harry
    公开号:US20160304515A1
    公开(公告)日:2016-10-20
    The present invention provides compounds of Formula (I) (Formula (I)) including pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.
  • [EN] INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL<br/>[FR] INHIBITEURS DU CANAL POTASSIQUE MÉDULLAIRE EXTERNE RÉNAL
    申请人:MERCK SHARP & DOHME
    公开号:WO2015095097A3
    公开(公告)日:2015-10-01
查看更多